Andere Sprachen Takeda Pharmaceutical Company Limited BOERSE MUENCHEN

Aktien

853849

JP3463000004

TKD

Realtime BOERSE MUENCHEN Andere Börsenplätze 08:00:04 25.06.2024			% 5 Tage	% 1. Jan.
24,51 ^EUR	+1,87 %		-2,47 %	-7,07 %

24.06.	Hutchmed China stellt fest, dass Takeda die EU-Zulassung für Fruzaqla erhalten hat	AN
24.06.	Takedas Medikament zur Behandlung von Organtransplantationsinfektionen von den japanischen Aufsichtsbehörden genehmigt	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Hutchmed China notes Takeda obtains EU approval for Fruzaqla	24.06.
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators	24.06.
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment	24.06.
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies	24.06.
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare	24.06.
Japanese Shares End Higher as BoJ Indicates Readiness for Policy Shifts	24.06.
Takeda Receives European Commission Approval for Colorectal Cancer Treatment	24.06.
Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)	24.06.
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	23.06.
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	23.06.
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla	21.06.
Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment	21.06.
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer	21.06.
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	21.06.
Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older	21.06.
Les sorcières épouvantent l'IA	21.06.
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes	21.06.
En Direct des Marchés : LVMH, Accor, Alstom, Atos, Casino, Plastivaloire, Boeing, Geberit...	21.06.
Borsa di Italia: Le streghe terrorizzano l'AI	21.06.
Bolsa de Madrid: Las brujas aterrorizan a la IA	21.06.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Takeda Pharmaceutical Company Limited BOERSE MUENCHEN

Aktien

853849

JP3463000004

TKD

Andere Sprachen

Filter